首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

2023942

細胞療法市場預測——全球分析（按治療方法類型、細胞類型、治療方法、工藝、應用、最終用戶和地區分類）——2034年

Cell Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Cell Type, Therapy Modality, Process, Application, End User, and By Geography

出版日期: 2026年04月17日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球細胞治療市場預計到 2026 年將達到 94 億美元，並在預測期內以 20.3% 的複合年成長率成長，到 2034 年將達到 412 億美元。

細胞療法是治療方法將活細胞輸注給患者，以修復、替換或再生受損組織，並治療癌症、神經系統疾病和自體免疫疾病等疾病的治療方法。這種創新方法涵蓋了從注射未經修飾的幹細胞到注射經過基因改造、靶向特定惡性腫瘤的免疫細胞等多種途徑。此領域涉及複雜的流程，包括細胞採集、分離、增殖、基因改造、冷凍保存和專業物流。隨著監管核准的加速和生產能力的成熟，細胞療法正從個人化、小規模的治療轉向擴充性、商業性化的治療平台。

癌症和慢性病發生率增加

全球癌症發生率持續上升，對先進治療方法的需求激增，尤其是在骨髓惡性腫瘤和固態腫瘤領域，傳統治療方法在這些領域療效不佳。細胞療法，特別是嵌合體抗原受體T細胞（CAR-T）產品，在難治性血液系統癌症患者中展現出顯著的完全緩解率，帶來了前所未有的臨床發展勢頭。糖尿病、心血管疾病和退化性疾病等慢性疾病的出現，進一步拓展了再生細胞療法在臨床開發中的潛在應用。這種持續的疾病負擔，加上全球人口老化，確保了持續的投資和臨床需求，從而推動細胞療法市場在學術界和商業領域的蓬勃發展。

高昂的醫療費用和報銷障礙

單次細胞療法療程的費用通常超過50萬美元，即使在擁有完善保險體系的先進醫療系統中，也構成了一道難以逾越的門檻。這些高昂的費用反映了自體療法固有的複雜、針對特定患者的生產流程以及嚴格的品管要求。各保險公司的報銷政策仍有差異，一些保險公司甚至要求患者在核准前領先多次失敗，這不僅延誤了患者的治療，也限制了其商業性可行性。儘管基於療效的支付模式正在興起，但仍處於試驗階段。同時，臨床規模生產所需的大量初始基礎設施投資也使得許多醫療機構無法提供此類療法，儘管臨床療效已得到證實，但市場擴張仍受到嚴重限制。

同種異體預製細胞療法的進展

源自供體的通用細胞產品無需針對特定患者進行客製化生產，有望徹底改變治療的可及性和成本效益。異基因移植方法能夠實現大規模、標準化的生產批次，與自體療法相比，可顯著降低每位患者的治療成本和前置作業時間。這些預製產品可以儲存、進行品質檢測並分發到多個治療中心，從而將細胞療法從客製化服務轉變為常規的製藥模式。基因編輯技術（尤其是CRISPR技術）的進步，使研究人員能夠在提高療效的同時降低移植物抗宿主疾病（GVHD）的風險。這種生產模式的轉變使細胞療法在經濟上對更廣泛的患者群體具有可行性，並開闢了巨大的市場機會。

製造複雜性和供應鏈脆弱性

由於原料的生物來源和生物過程的複雜性，細胞療法的生產仍然極易受到污染、偏差和批次缺陷的影響。單一缺陷批次可能導致患者治療延遲數月，產品召回甚至可能危及生命。冷凍保存細胞的低溫運輸要求非常嚴格，運輸過程中的溫度偏差可能會毀掉整批產品。生產設施的地理集中也增加了供應風險，例如自然災害和監管部門的停工。隨著核准細胞療法數量的增加，這些營運風險也隨之加劇，不僅威脅到患者獲得可靠治療的機會，還可能帶來法律責任風險，阻礙新進業者或限制該領域的投資。

新冠疫情的感染疾病：

新冠疫情透過轉移醫院資源、延誤臨床試驗以及中斷病患血液採集等方式，擾亂了細胞治療市場。許多大學附屬醫院推遲了非緊急的細胞治療程序，以便將重症監護資源用於對抗疫情。由於疫情導致需求激增，專用試劑和病毒載體的供應鏈面臨巨大壓力。然而，這場危機也加速了分散式生產模式、遠端品質監控系統和數位化供應鏈追蹤技術的應用。疫情凸顯了細胞療法分銷所需的韌性，並促使物流標準得到提升，這將為市場帶來長期的益處。目前市場復甦強勁，先前停滯的治療和臨床試驗的重啟推動了疫情後的成長。

在預測期內，基因改造細胞療法領域預計將成為最大的細分市場。

預計在預測期內，基因修飾細胞療法領域將佔據最大的市場佔有率，這反映了Kymriah和Yescarta等CAR-T產品的商業性成功和臨床影響。這些基因修飾療法透過重編程患者的免疫細胞來識別和清除癌細胞，在侵襲性白血病和淋巴瘤的治療中取得了前所未有的療效。除了腫瘤學領域，基因修飾療法的應用範圍正在擴展到自體免疫疾病、鐮狀細胞貧血和固體癌，而採用CRISPR和鹼基編輯技術的下一代基因編輯技術正在提高其安全性和有效性。儘管單次治療費用較高、適應症不斷擴大、區域性核准數量增加，以及人們對異基因移植作為替代方案的興趣日益濃厚，但預計該治療方法仍將在整個預測期內保持其市場主導地位。

在預測期內，基因改造領域預計將呈現最高的複合年成長率。

在預測期內，基因修飾領域預計將呈現最高的成長率，這主要得益於病毒載體設計、非病毒遞送系統和精準基因編輯平台的持續創新。這個關鍵過程涉及將治療性基因改造導入採集的患者或供體細胞，或破壞致病基因序列。與傳統的慢病毒方法相比，CRISPR-Cas9、TALENs 和基於轉座子的系統等新興技術能夠實現更有效率、更安全、更具可擴展性的基因修飾。下一代治療方法（例如雙靶向 CAR 和邏輯閘電路）日益複雜，需要更精細的修飾方案。隨著核准基因修飾治療方法數量的增加以及同種異體移植產品對標準化編輯的需求，該領域的成長速度已超過其他製程階段。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於美國——全球細胞療法創新和商業化的中心。該地區擁有大多數已通過核准的產品、主要的學術研究中心以及諾華、吉利德和百時美施貴寶等主要企業。聯邦醫療保險和私人保險公司的優惠報銷政策，加上美國食品藥物管理局（FDA）的快速核准流程，正在加速產品上市。完善的血液採集網路、專業治療中心和冷鏈物流基礎設施為臨床應用提供了支援。大量創業投資湧入北美生技Start-Ups，預計將確保研發管線的持續發展，並在整個預測期內鞏固該地區的市場領導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於政府對細胞療法研究的大力投入、龐大的患者群體以及醫療基礎設施的快速發展。中國已確立其領先地位，眾多國產CAR-T產品核准，且價格遠低於西方同類產品。日本的再生醫學法規結構（包括有條件早期核准途徑）正在加速市場准入。韓國和新加坡正在建立專業的製造地和臨床試驗系統。該地區癌症發生率高，加上中產階級醫療費用支出不斷成長，正在催生巨大的市場需求。隨著產能的擴大和監管的協調統一，亞太地區將成為細胞療法成長最快的區域市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要企業進行SWOT分析（最多3家公司）
區域細分
- 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第12章策略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第13章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第14章：公司簡介

Novartis AG
Gilead Sciences Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Bluebird Bio Inc.
Mesoblast Limited
Astellas Pharma Inc.
Fate Therapeutics Inc.
Legend Biotech Corporation
Adaptimmune Therapeutics plc
Allogene Therapeutics Inc.
CRISPR Therapeutics AG

簡介目錄圖表

Product Code: SMRC35154

According to Stratistics MRC, the Global Cell Therapy Market is accounted for $9.4 billion in 2026 and is expected to reach $41.2 billion by 2034 growing at a CAGR of 20.3% during the forecast period. Cell therapy involves the administration of living cells to patients to repair, replace, or regenerate damaged tissues and treat diseases including cancer, neurological disorders, and autoimmune conditions. This innovative approach ranges from unmodified stem cell infusions to genetically engineered immune cells designed to target specific malignancies. The market encompasses complex workflows including cell collection, isolation, expansion, genetic modification, cryopreservation, and specialized logistics. As regulatory approvals accelerate and manufacturing capabilities mature, cell therapy is transitioning from personalized, small-batch treatments toward scalable, commercially viable therapeutic platforms.

Market Dynamics:

Driver:

Rising incidence of cancer and chronic diseases

Global cancer rates continue to climb, with hematologic malignancies and solid tumors driving urgent demand for advanced therapeutic options where conventional treatments have limited efficacy. Cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) products, have demonstrated remarkable complete remission rates in patients with refractory blood cancers, creating unprecedented clinical momentum. Chronic conditions such as diabetes, cardiovascular disease, and degenerative disorders further expand potential applications as regenerative cell therapies progress through clinical development. This persistent disease burden, combined with aging populations worldwide, ensures sustained investment and clinical demand that propels the cell therapy market forward across both academic and commercial settings.

Restraint:

Prohibitively high treatment costs and reimbursement barriers

Individual cell therapy courses frequently exceed $500,000, creating substantial access barriers even in developed healthcare systems with robust insurance frameworks. These costs reflect the complex, patient-specific manufacturing processes and extensive quality control requirements that characterize autologous therapies. Reimbursement decisions remain inconsistent across payers, with some insurers requiring multiple prior treatment failures before approval, delaying patient access and limiting commercial viability. Outcome-based payment models are emerging but remain experimental, while the substantial upfront infrastructure investment required for clinical-scale manufacturing prevents many healthcare providers from offering these treatments, significantly constraining market expansion despite demonstrated clinical benefits.

Opportunity:

Advancements in allogeneic off-the-shelf cell therapies

Donor-derived universal cell products that eliminate the need for patient-specific manufacturing are poised to revolutionize treatment accessibility and economics. Allogeneic approaches enable large-scale, standardized production batches, dramatically reducing per-patient costs and lead times compared to autologous alternatives. These off-the-shelf products can be stored, quality tested, and distributed to multiple treatment centers, transforming cell therapy from a bespoke service into a conventional pharmaceutical model. Advances in gene editing technologies, particularly CRISPR, allow researchers to reduce graft-versus-host disease risks while enhancing therapeutic potency. This manufacturing paradigm shift opens substantial market opportunities by making cell therapies economically viable for broader patient populations.

Threat:

Manufacturing complexity and supply chain vulnerabilities

Cell therapy production remains exceptionally vulnerable to contamination, deviations, and batch failures due to the living nature of starting materials and the sensitivity of biological processes. Single lot failures can delay patient treatment by months, while product recalls carry life-threatening consequences. The cold chain requirements for cryopreserved cells are stringent, with temperature excursions during transport potentially destroying entire batches. Geographic concentration of manufacturing facilities creates supply risks from natural disasters or regulatory shutdowns. As the number of approved cell therapies increases, these operational risks compound, threatening reliable patient access and creating liability exposures that may discourage new entrants or limit investment in the sector.

Covid-19 Impact:

The COVID-19 pandemic disrupted cell therapy markets by diverting hospital resources, delaying clinical trials, and interrupting patient apheresis collections. Many academic medical centers postponed non-urgent cell therapy procedures to allocate intensive care capacity to virus response. Supply chains for specialized reagents and viral vectors faced significant strain as pandemic-related demand surged simultaneously. However, the crisis also accelerated adoption of decentralized manufacturing models, remote quality oversight systems, and digital supply chain tracking technologies. The pandemic demonstrated the resilience required for cell therapy distribution, leading to improved logistics standards that will benefit the market long term. Recovery has been strong, with backlogged treatments and renewed clinical trial momentum driving post-pandemic growth.

The Gene-Modified Cell Therapy segment is expected to be the largest during the forecast period

The Gene-Modified Cell Therapy segment is expected to account for the largest market share during the forecast period, reflecting the commercial success and clinical impact of CAR-T products such as Kymriah and Yescarta. These engineered therapies reprogram patient immune cells to recognize and eliminate cancer cells, achieving unprecedented response rates in aggressive leukemias and lymphomas. Beyond oncology, gene-modified approaches are expanding into autoimmune diseases, sickle cell anemia, and solid tumors, with next-generation edits using CRISPR and base-editing technologies enhancing safety and potency. The substantial per-patient pricing, combined with expanding indications and geographic approvals, ensures this modality maintains market dominance throughout the forecast timeline despite growing interest in allogeneic alternatives.

The Genetic Modification segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Genetic Modification segment is predicted to witness the highest growth rate, driven by continuous innovation in viral vector design, non-viral delivery systems, and precise gene-editing platforms. This critical process step involves introducing therapeutic transgenes or disrupting disease-causing genetic sequences within harvested patient or donor cells. Emerging technologies including CRISPR-Cas9, TALENs, and transposon-based systems are enabling more efficient, safer, and scalable modifications compared to traditional lentiviral approaches. The increasing complexity of next-generation therapies, such as dual-targeting CARs and logic-gated circuits, demands more sophisticated modification protocols. As the number of gene-modified therapy approvals rises and allogeneic products require standardized editing, this segment's growth outpaces other process steps.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, anchored by the United States as the global epicenter of cell therapy innovation and commercialization. The region hosts the majority of approved products, leading academic research centers, and dominant industry players including Novartis, Gilead, and Bristol-Myers Squibb. Favorable reimbursement policies through Medicare and private insurers, combined with the FDA's expedited approval pathways, accelerate product launches. Extensive infrastructure for apheresis collection networks, specialized treatment centers, and cryogenic logistics supports clinical adoption. Substantial venture capital funding flowing into North American biotech startups ensures continued pipeline advancement, reinforcing the region's market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by aggressive government investments in cell therapy research, large patient populations, and rapidly improving healthcare infrastructure. China has emerged as a leader, with numerous domestically developed CAR-T products gaining approval and pricing substantially below Western equivalents. Japan's regulatory framework for regenerative medicine, including conditional early approval pathways, accelerates market entry. South Korea and Singapore are establishing specialized manufacturing hubs and clinical trial capabilities. The region's high cancer incidence rates, combined with growing middle-class healthcare spending, create immense demand. As manufacturing capacity expands and regulatory harmonization progresses, Asia Pacific becomes the fastest-growing regional market for cell therapies.

Key players in the market

Some of the key players in Cell Therapy Market include Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Mesoblast Limited, Astellas Pharma Inc., Fate Therapeutics Inc., Legend Biotech Corporation, Adaptimmune Therapeutics plc, Allogene Therapeutics Inc., and CRISPR Therapeutics AG.

Key Developments:

In April 2026, BMS launched a new patient support initiative celebrating ten years of multiple myeloma care, emphasizing increased access to Abecma for underserved communities.

In March 2026, CRISPR Therapeutics AG announced the advancement of its in vivo CAR-T platform, utilizing proprietary lipid nanoparticles (LNPs) to target autoimmune diseases, with clinical trials expected to initiate mid-year.

In July 2025, Adaptimmune Therapeutics plc signed a definitive agreement to sell its key cell therapy assets-including Tecelra, lete-cel, and afami-cel-to US WorldMeds to ensure continued patient access while Adaptimmune focuses on early-stage R&D.

Therapy Types Covered:

Autologous Cell Therapy
Allogeneic Cell Therapy

Cell Types Covered:

Stem Cells
Immune Cells
Other Cell Types

Therapy Modalities Covered:

Gene-Modified Cell Therapy
Non-Modified Cell Therapy

Process Covered:

Cell Collection
Cell Isolation & Selection
Cell Expansion
Genetic Modification
Cell Processing & Formulation
Storage & Cryopreservation
Distribution & Logistics

Applications Covered:

Oncology
Cardiovascular Diseases
Neurological Disorders
Musculoskeletal Disorders
Autoimmune Diseases
Dermatology & Wound Healing
Other Applications

End Users Covered:

Hospitals & Clinics
Specialty Treatment Centers
Academic & Research Institutes
Biopharmaceutical & Biotechnology Companies

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Cell Therapy Market, By Therapy Type

5.1 Autologous Cell Therapy
5.2 Allogeneic Cell Therapy

6 Global Cell Therapy Market, By Cell Type

6.1 Stem Cells
- 6.1.1 Hematopoietic Stem Cells
- 6.1.2 Mesenchymal Stem Cells
- 6.1.3 Induced Pluripotent Stem Cells (iPSCs)
6.2 Immune Cells
- 6.2.1 T Cells
- 6.2.2 CAR-T Cells
- 6.2.3 TCR-T Cells
- 6.2.4 Natural Killer (NK) Cells
- 6.2.5 Dendritic Cells
6.3 Other Cell Types

7 Global Cell Therapy Market, By Therapy Modality

7.1 Gene-Modified Cell Therapy
7.2 Non-Modified Cell Therapy

8 Global Cell Therapy Market, By Process

8.1 Cell Collection
8.2 Cell Isolation & Selection
8.3 Cell Expansion
8.4 Genetic Modification
8.5 Cell Processing & Formulation
8.6 Storage & Cryopreservation
8.7 Distribution & Logistics

9 Global Cell Therapy Market, By Application

9.1 Oncology
9.2 Cardiovascular Diseases
9.3 Neurological Disorders
9.4 Musculoskeletal Disorders
9.5 Autoimmune Diseases
9.6 Dermatology & Wound Healing
9.7 Other Applications

10 Global Cell Therapy Market, By End User

10.1 Hospitals & Clinics
10.2 Specialty Treatment Centers
10.3 Academic & Research Institutes
10.4 Biopharmaceutical & Biotechnology Companies

11 Global Cell Therapy Market, By Geography

11.1 North America
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
11.2 Europe
- 11.2.1 United Kingdom
- 11.2.2 Germany
- 11.2.3 France
- 11.2.4 Italy
- 11.2.5 Spain
- 11.2.6 Netherlands
- 11.2.7 Belgium
- 11.2.8 Sweden
- 11.2.9 Switzerland
- 11.2.10 Poland
- 11.2.11 Rest of Europe
11.3 Asia Pacific
- 11.3.1 China
- 11.3.2 Japan
- 11.3.3 India
- 11.3.4 South Korea
- 11.3.5 Australia
- 11.3.6 Indonesia
- 11.3.7 Thailand
- 11.3.8 Malaysia
- 11.3.9 Singapore
- 11.3.10 Vietnam
- 11.3.11 Rest of Asia Pacific
11.4 South America
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Colombia
- 11.4.4 Chile
- 11.4.5 Peru
- 11.4.6 Rest of South America
11.5 Rest of the World (RoW)
- 11.5.1 Middle East
  - 11.5.1.1 Saudi Arabia
  - 11.5.1.2 United Arab Emirates
  - 11.5.1.3 Qatar
  - 11.5.1.4 Israel
  - 11.5.1.5 Rest of Middle East
- 11.5.2 Africa
  - 11.5.2.1 South Africa
  - 11.5.2.2 Egypt
  - 11.5.2.3 Morocco
  - 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives

14 Company Profiles

14.1 Novartis AG
14.2 Gilead Sciences Inc.
14.3 Bristol-Myers Squibb Company
14.4 F. Hoffmann-La Roche Ltd.
14.5 Johnson & Johnson
14.6 Pfizer Inc.
14.7 Takeda Pharmaceutical Company Limited
14.8 Bluebird Bio Inc.
14.9 Mesoblast Limited
14.10 Astellas Pharma Inc.
14.11 Fate Therapeutics Inc.
14.12 Legend Biotech Corporation
14.13 Adaptimmune Therapeutics plc
14.14 Allogene Therapeutics Inc.
14.15 CRISPR Therapeutics AG

簡介目錄圖表

List of Tables

Table 1 Global Cell Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Cell Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
Table 3 Global Cell Therapy Market Outlook, By Autologous Cell Therapy (2023-2034) ($MN)
Table 4 Global Cell Therapy Market Outlook, By Allogeneic Cell Therapy (2023-2034) ($MN)
Table 5 Global Cell Therapy Market Outlook, By Cell Type (2023-2034) ($MN)
Table 6 Global Cell Therapy Market Outlook, By Stem Cells (2023-2034) ($MN)
Table 7 Global Cell Therapy Market Outlook, By Hematopoietic Stem Cells (2023-2034) ($MN)
Table 8 Global Cell Therapy Market Outlook, By Mesenchymal Stem Cells (2023-2034) ($MN)
Table 9 Global Cell Therapy Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2023-2034) ($MN)
Table 10 Global Cell Therapy Market Outlook, By Immune Cells (2023-2034) ($MN)
Table 11 Global Cell Therapy Market Outlook, By T Cells (2023-2034) ($MN)
Table 12 Global Cell Therapy Market Outlook, By CAR-T Cells (2023-2034) ($MN)
Table 13 Global Cell Therapy Market Outlook, By TCR-T Cells (2023-2034) ($MN)
Table 14 Global Cell Therapy Market Outlook, By Natural Killer (NK) Cells (2023-2034) ($MN)
Table 15 Global Cell Therapy Market Outlook, By Dendritic Cells (2023-2034) ($MN)
Table 16 Global Cell Therapy Market Outlook, By Other Cell Types (2023-2034) ($MN)
Table 17 Global Cell Therapy Market Outlook, By Therapy Modality (2023-2034) ($MN)
Table 18 Global Cell Therapy Market Outlook, By Gene-Modified Cell Therapy (2023-2034) ($MN)
Table 19 Global Cell Therapy Market Outlook, By Non-Modified Cell Therapy (2023-2034) ($MN)
Table 20 Global Cell Therapy Market Outlook, By Process (2023-2034) ($MN)
Table 21 Global Cell Therapy Market Outlook, By Cell Collection (2023-2034) ($MN)
Table 22 Global Cell Therapy Market Outlook, By Cell Isolation & Selection (2023-2034) ($MN)
Table 23 Global Cell Therapy Market Outlook, By Cell Expansion (2023-2034) ($MN)
Table 24 Global Cell Therapy Market Outlook, By Genetic Modification (2023-2034) ($MN)
Table 25 Global Cell Therapy Market Outlook, By Cell Processing & Formulation (2023-2034) ($MN)
Table 26 Global Cell Therapy Market Outlook, By Storage & Cryopreservation (2023-2034) ($MN)
Table 27 Global Cell Therapy Market Outlook, By Distribution & Logistics (2023-2034) ($MN)
Table 28 Global Cell Therapy Market Outlook, By Application (2023-2034) ($MN)
Table 29 Global Cell Therapy Market Outlook, By Oncology (2023-2034) ($MN)
Table 30 Global Cell Therapy Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
Table 31 Global Cell Therapy Market Outlook, By Neurological Disorders (2023-2034) ($MN)
Table 32 Global Cell Therapy Market Outlook, By Musculoskeletal Disorders (2023-2034) ($MN)
Table 33 Global Cell Therapy Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
Table 34 Global Cell Therapy Market Outlook, By Dermatology & Wound Healing (2023-2034) ($MN)
Table 35 Global Cell Therapy Market Outlook, By Other Applications (2023-2034) ($MN)
Table 36 Global Cell Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 37 Global Cell Therapy Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 38 Global Cell Therapy Market Outlook, By Specialty Treatment Centers (2023-2034) ($MN)
Table 39 Global Cell Therapy Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
Table 40 Global Cell Therapy Market Outlook, By Biopharmaceutical & Biotechnology Companies (2023-2034) ($MN)